Sweden, Oct. 31 -- The launch of the Culturefuge 200 B separator opens new possibilities for pharmaceutical businesses of all sizes. They can now operate medium-scale processes, turning to high-density fermentation to boost productivity and maximize the yield of valuable biologics, such as monoclonal antibodies. The Culturefuge 200 B extends our successful Bactofuge(R) portfolio, bringing proven technology and gentle, continuous separation to medium-sized biopharma producers.The Culturefuge 200 B is built on Alfa Laval's unique Hermetic Design (TM) , already trusted by biopharma producers for gentle cell handling and best-in-class results. With integrated Bactofuge(R) technology, it enables continuous separation of high-density fermentation...